retatrutide heart Retatrutide, Tirzepatide and Survodutide in Research Understanding the Link: Arrhythmias &

Further investigation is necessary to determine safety and efficacy

We can often avoid some of those side effects if we increase the dose slowly and not just increase the dose once a month

Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al

When fat stores release toxins and metabolic byproducts, the burden falls on the cells primary defense system: Glutathione the bodys Master Antioxidant

To use the Medicare GLP-1 Bridge benefit, patients generally need to meet all of the following: Be enrolled in Medicare Part D (a standalone prescription drug plan or Medicare Advantage plan with prescription drug coverage) Be at least 18 years old AND meet one of three BMI-based eligibility tiers (more restrictive than the general FDA label): Tier 1: BMI of 35 or higher (no additional conditions required), or Tier 2: BMI of 30 or higher WITH heart failure with preserved ejection fraction, OR uncontrolled hypertension (systolic blood pressure above 140 mm Hg or diastolic above 90 mm Hg despite treatment with two antihypertensive medications), OR chronic kidney disease stage 3a or above, or Tier 3: BMI of 27 or higher WITH prediabetes (per American Diabetes Association guidelines), previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease Be using the medication in combination with current and ongoing lifestyle modification including structured nutrition and physical activity Have a prescription from a qualified prescriber (any licensed clinician with prescribing authority can prescribe

Injectable GHK-Cu: A Critical Distinction This distinction matters enormously from both a scientific and regulatory standpoint